- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: INCSHR1210 | SHR-1210
camrelizumab is an approved drug (China (2019))
Compound class: Antibody
Comment: Camrelizumab is a fully human anti-programmed cell death 1 (PD-1) monoclonal antibody being developed as an immuno-oncology therapeutic.
SARS-CoV-2 and COVID-19: Clinical efficacy of camrelizumab plus thymosin in patients with COVID-19 will be evaluated in clinical trial NCT04268537.
|No information available.|
|Summary of Clinical Use|
|More than 20 clinical trials assessing camrelizumab's anti-tumour activity are registered with ClinicalTrials.gov. The most advanced trials are two Phase 3 clinical trials evaluating camrelizumab's efficacy against lung cancer (NCT03134872) and esophageal carcinoma (NCT03099382). The first global approval of camrelizumab was granted by China in 2019, under which camrelizumab is indicated as a treatment for relapsed/refractory classical Hodgkin lymphoma .|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT03099382||Study of SHR-1210 Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal Cancer||Phase 3 Interventional||Jiangsu HengRui Medicine Co., Ltd.|
|NCT03134872||A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC||Phase 3 Interventional||Jiangsu HengRui Medicine Co., Ltd.|
|NCT04268537||Immunoregulatory Therapy for 2019-nCoV||Phase 2 Interventional||Southeast University, China||PD-1 blockade is anticipated to reduce the development of sepsis secondary to severe pneumonia and excessive inflammatory response syndrome in COVID-19 patients, by reversing sepsis-associated T cell depletion.|